Phase 1 (Safety and Dosage)

Choosing the right starting dose for a first-in-human (FIH) study is one of the most critical—and challenging—decisions in early clinical development. Pharmacometrics, the science of interpreting and describing pharmacology using mathematical models, plays an increasingly vital role in dose prediction, escalation, and optimization in Phase 1 trials. This article outlines the key pharmacometric tools, modeling strategies, and regulatory alignment that enable better-informed decisions and improve early trial success rates.
Click to read the full article.

Biomarkers play an increasingly critical role in early clinical development, particularly in Phase 1 trials where mechanistic insight and early signal detection are vital. They help characterize drug activity, confirm biological effects, and sometimes predict patient response. A well-planned biomarker strategy can accelerate decision-making, improve patient selection, and reduce risk in later stages. This article explores how to differentiate and deploy exploratory versus predictive biomarkers in Phase 1 trials, supported by regulatory guidance and real-world examples.
Click to read the full article.

With the rise of biologics, injectables, inhalers, wearable delivery systems, and on-body injectors, drug-device combination products are reshaping how therapies are administered. In early-phase trials, particularly Phase 1, these combinations pose unique challenges. Both the drug and the device must be evaluated for safety, usability, and compatibility—often under compressed timelines. This tutorial explores how to plan, design, and execute early-phase studies involving drug-device combinations with a focus on human factors, regulatory compliance, and integrated clinical endpoints.
Click to read the full article.

Phase 1 clinical trials primarily focus on safety, pharmacokinetics (PK), and tolerability in healthy volunteers or patients. While not always required, blinding and randomization can significantly enhance the scientific rigor and credibility of early-phase data—particularly when subjective assessments or placebo responses may affect interpretation. This tutorial explains the key considerations for applying blinding and randomization in Phase 1 study designs, including benefits, practical implementation, ethical issues, and regulatory expectations.
Click to read the full article.

First-in-human (FIH) studies represent a pivotal milestone in drug development but also carry the highest degree of uncertainty and risk. These early-phase trials require precise operational planning, stringent safety monitoring, and proactive communication. Operational risk management in FIH trials is essential to protect participants, ensure data integrity, and enable efficient dose escalation decisions. This guide provides a practical framework for identifying, mitigating, and managing operational risks in FIH clinical trials.
Click to read the full article.

Phase 1 clinical trials in rare diseases present a unique set of challenges. Unlike traditional early-phase studies that enroll healthy volunteers, trials for rare conditions often require patient participation from the outset. This is due to ethical considerations, unique pathophysiology, and lack of healthy correlates. With small, geographically dispersed populations and heterogeneous phenotypes, designing scientifically sound and ethically robust Phase 1 trials for rare diseases demands creativity, regulatory insight, and flexible design strategies.
Click to read the full article.

Pediatric Phase 1 clinical trials are crucial for understanding how drugs behave in children, but they come with heightened ethical scrutiny and regulatory complexity. Children are a vulnerable population, and involving them in early-phase trials—especially when risks are unknown—requires a rigorous justification and protective framework. This article outlines the ethical, operational, and regulatory challenges of pediatric Phase 1 trials and offers practical strategies to design and conduct them responsibly.
Click to read the full article.

In early clinical development, demonstrating product comparability is critical for both generic small-molecule drugs and biosimilar biologics. While both involve head-to-head assessments with reference products, the scientific and regulatory requirements differ significantly. This article explores the key differences between bioequivalence (BE) and biosimilarity assessments in Phase 1 trials, covering study designs, pharmacokinetic/pharmacodynamic (PK/PD) endpoints, statistical methods, and global regulatory expectations.
Click to read the full article.

Topical and transdermal drug delivery systems offer localized or systemic therapeutic effects through skin application. While convenient and non-invasive, these formulations pose unique challenges during early-phase testing. Phase 1 clinical trials for such products must evaluate dermal absorption, site-specific reactions, systemic exposure, and formulation tolerability. This article outlines the strategic considerations, design adaptations, and regulatory nuances involved in conducting Phase 1 trials for topical and transdermal drugs.
Click to read the full article.

Controlled Human Infection Models (CHIM), also known as human challenge studies, are a powerful and controversial tool in early vaccine development. In CHIM studies, healthy volunteers are deliberately exposed to a pathogen under tightly controlled conditions to assess vaccine safety, immunogenicity, and early efficacy. When executed ethically and scientifically, CHIMs can accelerate vaccine development timelines and reduce uncertainty ahead of large-scale trials. This article explores how CHIMs are integrated into Phase 1 or early Phase 2 studies, with an emphasis on trial design, risk mitigation, and global regulatory guidance.
Click to read the full article.